ERBB2 and breast carcinoma: A total of 20 randomized controlled trials (RCTs) were included in this study, investigating the effectiveness of four CDK4/6 inhibitors—Abemaciclib, Dalpiciclib, Ribociclib, and Palbociclib—when combined with ET for the treatment of HR+/HER2-breast cancer.